NFKB1 and cancer: RIPK2 contributes to both proliferation and invasion in cancers such as ovarian and gastric cancers, mediates NOD1 to regulate the NF-κB pathway, and promotes immunotherapy resistance by triggering cytotoxic T lymphocyte dysfunction, which is highly detrimental to prognosis24,25.